Samuel King, MD
Cardiovascular Disease · Orangeburg, SCNPI 1295800613
Payments from drug & device makers
Across 277 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$564
- E.r. Squibb & Sons, L.L.C.$554
- Amgen$546
- Pfizer$456
- Sanofi-aventis U.S. LLC$322
- Merck$233
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,19499%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 43 | $564 |
| E.r. Squibb & Sons, L.L.C. | 40 | $554 |
| Amgen(2 entities) | 36 | $546 |
| Pfizer | 32 | $456 |
| Sanofi-aventis U.S. LLC | 18 | $322 |
| Merck | 16 | $233 |
| Novartis | 16 | $205 |
| AstraZeneca | 6 | $144 |
| Abbott | 7 | $143 |
| Boehringer Ingelheim | 8 | $117 |
| Biotronik Inc. | 6 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $96 |
| Boston Scientific | 4 | $77 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Terumo Medical Corporation | 3 | $48 |
| Chiesi USA, Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Portola Pharmaceuticals, LLC | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 3 | $45 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Getinge USA Sales, LLC | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 3 | $40 |
| Medicomp Inc | 1 | $35 |
| Bardy Diagnostics, Inc. | 2 | $26 |
| AbbVie | 1 | $24 |
| Atricure, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $15 |
| Baudax Bio Inc. | 1 | $14 |
| G Medical Diagnostic Services, Inc. | 1 | $14 |
| Cashflow Solutions, LLC | 1 | $13 |
| Cvrx, Inc. | 1 | $12 |
How this compares
$4,226 in reported general payments places this provider in the 50th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 484 | $352,480 |
| XareltoRivaroxaban | 104 | $88,612 |
| EntrestoSacubitril/Valsartan | 90 | $88,355 |
| MultaqDronedarone Hcl | 70 | $86,055 |
| Repatha SureclickEvolocumab | 65 | $41,283 |
| JardianceEmpagliflozin | 20 | $20,753 |
| NexlizetBempedoic Acid/Ezetimibe | 24 | $9,386 |
| FarxigaDapagliflozin Propanediol | 11 | $9,385 |
| NexletolBempedoic Acid | 14 | $5,701 |
| VascepaIcosapent Ethyl | 15 | $5,137 |
| SotalolSotalol Hcl | 173 | $3,892 |
| Metoprolol Succinate | 315 | $3,464 |
| Rosuvastatin Calcium | 152 | $2,865 |
| Amlodipine Besylate | 340 | $2,013 |
| Dofetilide | 28 | $1,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $456 | $352,480484 claims |
| Johnson & JohnsonXarelto | $564 | $88,612104 claims |
| NovartisEntresto | $205 | $88,35590 claims |
| Sanofi-aventis U.S. LLCMultaq | $322 | $86,05570 claims |
| Boehringer IngelheimJardiance | $117 | $20,75320 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $56 | $15,08738 claims |
| AstraZenecaFarxiga | $144 | $9,38511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Orangeburg
- Brent McLaurinAnderson$1.1M
- Robert BiedermanCharleston$801K
- James MerriamGreenville$728K
- Vipul ShahLancaster$488K
- Arthur EberlyGreenville$438K
- Gregory SanGreenville$429K
- Naresh MoriRock Hill$408K
- Priya KumarGreenwood$351K
- Dev VazGreenville$257K
- William YarbroughCharleston$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.